Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 81201887

Next Previous
Drug Profile

JNJ 81201887

Alternative Names: AAVCAGsCD59; HMR59; JNJ-1887; JNJ-81201887

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tufts University
  • Developer Hemera Biosciences; Johnson & Johnson Innovative Medicine
  • Class Eye disorder therapies; Gene therapies; Recombinant proteins
  • Mechanism of Action Complement system protein inhibitors; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Dry age-related macular degeneration
  • No development reported Wet age-related macular degeneration

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for phase-I development in Wet age-related macular degeneration(In the elderly, In adults) in USA (Intravitreous, Injection)
  • 19 Sep 2024 Johnson & Johnson Innovative Medicine initiates phase-II clinical trials for Dry age-related macular degeneration (In the elderly, In adults) in USA (Intravitreous) (NCT06635148)
  • 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top